Helus Pharma CEO to Present at Morgan Stanley Healthcare Conference

Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat will be webcast live on September 16 at 8:30 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma’s investor relations website. To view the full press release, visit https://ibn.fm/r0jfC.

The invitation to present at one of the most prestigious healthcare investment conferences underscores Helus Pharma’s growing visibility in the biotech sector. Morgan Stanley’s Global Healthcare Conference attracts top institutional investors, analysts, and industry executives, providing a platform for companies to showcase their pipelines and strategic visions. For Helus Pharma, this exposure could enhance its profile among potential investors and partners, especially as it advances its novel serotonergic agonists (NSAs) through clinical trials.

Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health.

The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma also has an extensive research portfolio of investigational NSAs.

The timing of this presentation is significant. Mental health disorders affect millions worldwide, and existing treatments often fall short for many patients. Helus Pharma’s focus on NSAs represents a promising avenue for addressing these gaps. The Breakthrough Therapy Designation for HLP003 highlights the potential of its approach and may expedite its development and review process. Positive data from ongoing trials could position Helus Pharma as a leader in the mental health therapeutics space.

Operating in Canada, the United States, the United Kingdom, and Ireland, Helus Pharma is well-positioned to conduct global clinical trials and eventually commercialize its products. For company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Helus Pharma™ is a trademark of Cybin Corp.

Investors and industry watchers should note that the latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP. As the conference date approaches, the fireside chat could provide valuable insights into Helus Pharma’s strategic direction and the potential of its NSA pipeline, making it a key event for those tracking developments in mental health treatment.